
Estrella Immunopharma Showcases Updated EB103 Data at 2026 ASTCT® & CIBMTR® Tandem Meetings
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune…











